CN1803203A - Soluble hemostatic gauze for diminishing inflammation, killing bacteria and calming pain, and its making method - Google Patents
Soluble hemostatic gauze for diminishing inflammation, killing bacteria and calming pain, and its making method Download PDFInfo
- Publication number
- CN1803203A CN1803203A CN 200510135360 CN200510135360A CN1803203A CN 1803203 A CN1803203 A CN 1803203A CN 200510135360 CN200510135360 CN 200510135360 CN 200510135360 A CN200510135360 A CN 200510135360A CN 1803203 A CN1803203 A CN 1803203A
- Authority
- CN
- China
- Prior art keywords
- gauze
- add
- soluble stanching
- sodium
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002439 hemostatic effect Effects 0.000 title abstract description 7
- 206010061218 Inflammation Diseases 0.000 title abstract description 5
- 238000000034 method Methods 0.000 title abstract description 5
- 241000894006 Bacteria Species 0.000 title abstract description 3
- 230000036407 pain Effects 0.000 title abstract description 3
- 230000001914 calming effect Effects 0.000 title abstract 2
- 230000003467 diminishing effect Effects 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 13
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 13
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 13
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 12
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 12
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 12
- 229960001631 carbomer Drugs 0.000 claims abstract description 12
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims abstract description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 12
- 239000000661 sodium alginate Substances 0.000 claims abstract description 12
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 12
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 7
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 7
- 239000000047 product Substances 0.000 claims description 26
- 230000000202 analgesic effect Effects 0.000 claims description 24
- 230000003115 biocidal effect Effects 0.000 claims description 21
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 18
- 230000001476 alcoholic effect Effects 0.000 claims description 17
- 235000001014 amino acid Nutrition 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 239000003093 cationic surfactant Substances 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 229940008099 dimethicone Drugs 0.000 claims description 11
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 11
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 11
- 235000019800 disodium phosphate Nutrition 0.000 claims description 11
- 229910000397 disodium phosphate Inorganic materials 0.000 claims description 11
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 11
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000011265 semifinished product Substances 0.000 claims description 6
- 229960005274 benzocaine Drugs 0.000 claims description 5
- 229920000136 polysorbate Polymers 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 4
- 229960002233 benzalkonium bromide Drugs 0.000 claims description 3
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical group [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 claims description 3
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000002994 raw material Substances 0.000 abstract description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 125000002091 cationic group Chemical group 0.000 abstract 1
- JZZIHCLFHIXETF-UHFFFAOYSA-N dimethylsilicon Chemical compound C[Si]C JZZIHCLFHIXETF-UHFFFAOYSA-N 0.000 abstract 1
- 239000003921 oil Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 19
- 208000027418 Wounds and injury Diseases 0.000 description 19
- 239000000243 solution Substances 0.000 description 15
- 230000035876 healing Effects 0.000 description 13
- 238000012360 testing method Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000003672 processing method Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 208000031737 Tissue Adhesions Diseases 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 239000000835 fiber Substances 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 238000001035 drying Methods 0.000 description 4
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 4
- 229930185107 quinolinone Natural products 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- HHAGWXCTPQVPJV-UHFFFAOYSA-N N.[Br] Chemical compound N.[Br] HHAGWXCTPQVPJV-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000005214 Poroma Diseases 0.000 description 1
- GBFLZEXEOZUWRN-VKHMYHEASA-N S-carboxymethyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CSCC(O)=O GBFLZEXEOZUWRN-VKHMYHEASA-N 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- -1 carboxymethyl ester Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000001013 eccrine acrospiroma Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Disclosed is a soluble hemostatic gauze for diminishing inflammation, killing bacteria and calming pain, and its making method, which comprises the following raw materials (by weight portion), 0.1-0.3% of disodium hydrogen phosphate, 1-1.8% of sodium alginate, 0.5-2% of Carbomer, 1-10% of cationic surface active agent, 1-2% of polyethylene glycol, 1-4% of Tween-80, 0.1-1% of dimethyl silicon oil, 0.2-0.8% of sodium carboxymethylcellulose, 0.05% of benzocain and balancing ethanol solution.
Description
Technical field
A kind of antiinflammatory, antibiotic analgesic Solubility Hemostatic Gauze and Processing Method relate to the medical and hygiene article field.
Background technology
Present hospital gauze generally be by comprehensive fiber through spin, knit, defat, bleaching, dry, disinfect after, use for medical department, such gauze becomes the waste pollution environment after using, simultaneously after the wound incrustation, gauze can bond with wound, cause the secondary wound easily for taking off gauze when changing dressings, bring misery, be unfavorable for the timely healing of wound to the patient.Based on above-mentioned problem, people have invented soluble stanching gauze.Soluble stanching gauze is generally the product after the opposite fiber carries out defat and mystery processing, promptly pass through C, M, the NA content that the general method for making of C is made is at the SCMC of 6-8% (sodium carboxymethyl cellulose), as the Chinese patent patent No. is 91110511 and 98101676, soluble stanching gauze is clogged after the dipping antimicrobial treatment, cover various wounds, solubilized agglutination thing behind the liquid that the chance wound oozes out, produce a large amount of anion, play the activation thrombin, promote the generation of thrombin, platelet is condensed rapidly, stifled match blood capillary, thus play hemostasis, protect wound, protect from infection, promote the effect of wound healing.But the function of this soluble stanching gauze antibiotic and sterilizing is relatively poor, can not solve the problem of tissue adhesion.
A kind of antiinflammatory, antibiotic external used synthesized medicine, Solubility Hemostatic Gauze and Processing Method have been introduced among the Chinese patent ZL02135172.4, this synthetic drug is the chemical compound that quinolinones and aminoacid reaction back forms, and soluble anti-inflammation, antibiotic, hemostatic gauze comprise the chemical compound of soluble fiber and quinolinones and aminoacid reaction back formation; Soluble anti-inflammation, processing method antibiotic, hemostatic gauze comprise the following order step: (1) aminoacid and quinolinones are adjusted concentration to 5～30% (weight) in aqueous solution or ethanol water, react 0.5～30 hour; (2) reactant in the step (1) was mixed in the alcoholic solution of 80～95% (weight) 0.5～30 hour by 1.2～10 (weight ratios) with soluble fiber; (3) soluble fiber is taken out drying in solution.Wound site can directly be clogged, be covered to this gauze, and discharge monomer quinolinones and amino acid nutrient composition at wound, causes the secondary wound at the Shi Buhui that changes dressings, and wound healing is fast.But it is very stable and balanced that medicine and combining of soluble stanching gauze are not, medicine be not molecular structure with the best attached on the soluble stanching gauze, make the effect of disinfection not bring into play fully.
In addition, a kind of view is arranged in the prior art, think that the external application of analgesic has disadvantageous effect for the healing of wound, so prior art is generally with oral or injection analgesic.Wherein have a kind of viewpoint to think that analgesic benumbed peripheral nerve, human body can not in time be made a response to wound information like this, influences the reparation of wound; Also have a kind of viewpoint to think, the generation of the pair cell of analgesic own is influential, thereby influences the healing of wound.
Summary of the invention
An object of the present invention is for the function that solves soluble stanching gauze antibiotic and sterilizing in the above-mentioned prior art relatively poor, medicine is not that molecular structure with the best is attached on the soluble stanching gauze, make the effect of disinfection not bring into play fully, there is not analgesic activity, can not solve the problem of tissue adhesion, a kind of antiinflammatory, antibiotic analgesic soluble stanching gauze are provided.
Another object of the present invention provides the preparation method of a kind of antiinflammatory, antibiotic analgesic soluble stanching gauze.
For achieving the above object, a technical scheme of the present invention provides a kind of antiinflammatory, antibiotic analgesic soluble stanching gauze, constitute the sodium hydrogen phosphate of 0.1-0.3%, the sodium alginate of 1-1.8%, the carbomer of 0.5-2% by the material of following weight percentage ratio, the cationic surfactant of 1-10%, the Polyethylene Glycol of 1-2%, 1-4% tween 80,0.1-1% dimethicone, 0.2-0.8% sodium carboxymethyl cellulose, all the other are concentration greater than 80% alcoholic solution for 0.05% benzocaine.
The optimization formula of a kind of antiinflammatory of the present invention, antibiotic analgesic soluble stanching gauze: the material by following weight percentage ratio constitutes: the carbomer of 0.2% sodium hydrogen phosphate, the sodium alginate of 1.2-1.6%, 1-1.5%, the cationic surfactant of 5-8%, the Polyethylene Glycol of 1.2-1.8%, 2-3% tween 80,0.4-0.6% dimethicone, 0.4-0.6% sodium carboxymethyl cellulose, 0.05% benzocaine, all the other are the alcoholic solution of 85-95% for concentration.
The aminoacid that can also comprise 0-0.05% among the present invention.Described aminoacid is aminoacid of the prior art, as tryptophan, methionine, threonine, leucine, valine, phenylalanine etc.; Optimum ratio 0.01-0.02%.
For achieving the above object, another technical scheme of the present invention provides the preparation method of a kind of antiinflammatory, antibiotic analgesic soluble stanching gauze.
Configuration concentration is the alcoholic solution more than 80%, add sodium hydrogen phosphate, sodium alginate, carbomer, add cationic surfactant then, elevated temperature is to 45-85 ℃, stir, add soluble stanching gauze, stir or the condition of ultrasonic vibrations under carry out dynamic chemical and take out gauze after in conjunction with 0.5-60 hour, the continuous Polyethylene Glycol that adds in original liquid, tween 80, dimethicone, sodium carboxymethyl cellulose, the semi-finished product gauze is put into medicinal liquid, proceed dynamic chemical in conjunction with 1-30 hour under 45-85 ℃, take out, the drying with steam oven dry gets product.
Say the preparation method of a kind of antiinflammatory of the present invention, antibiotic analgesic soluble stanching gauze further.
Configuration concentration is the alcoholic solution of 85-99%, add aminoacid, elevated temperature is to 50-70 ℃, add glycerol, add cationic surfactant, the adjusting pH value is 8-12, boiling reflux 2-4 hour, add sodium hydrogen phosphate then, sodium alginate, carbomer, elevated temperature stirs to 50-70 ℃, add soluble stanching gauze, after dynamic chemical under the condition of stirring or ultrasonic vibrations was in conjunction with 3-15 hour, take out gauze, the continuous Polyethylene Glycol that adds in original liquid, tween 80, dimethicone, sodium carboxymethyl cellulose is put into medicinal liquid with the semi-finished product gauze, the adjusting pH value is 3-6.8, proceed dynamic chemical in conjunction with 4-20 hour under 50-70 ℃, take out, oven dry gets product.
Further say the preparation method of a kind of antiinflammatory of the present invention, antibiotic analgesic soluble stanching gauze.
Configuration concentration is the alcoholic solution of 85-95%, add aminoacid, the sodium hydrogen phosphate that adds 0.1-0.3%, the sodium alginate of 1-1.8%, the carbomer of 0.5-2%, the cationic surfactant that adds 1-10% then, elevated temperature to ℃, stir, add soluble stanching gauze, stir or the condition of ultrasonic vibrations under carry out dynamic chemical and take out gauze after in conjunction with 4-12 hour, the continuous Polyethylene Glycol that adds 1-2% in original liquid, the 1-4% tween 80, the 0.1-1% dimethicone, the 0.2-0.8% sodium carboxymethyl cellulose, the semi-finished product gauze is put into medicinal liquid, under 50-60 ℃, proceed dynamic chemical in conjunction with 8-15 hour, take out, the drying with steam oven dry gets product.
Beneficial effect:
Product of the present invention is compared with prior art products:
1. this product has antiseized, sterilization, antiinflammatory, stops blooding and certain debridement effect is arranged wound.
2. this product combines many combinations complex of anti-inflammation drugs and analgesic drug product for being carrier with the fiber carboxymethyl ester, and all the other products are one pack system in the prior art.
3. this product is except that possessing hemostasis at once, broad-spectrum antiseptic, promotion wound healing, also possesses unique pain relieving, prevents the function of tissue adhesion.This function is for reducing the patient suffering, and it is significant undoubtedly to improve patient's life quality.
4. because soluble stanching gauze is loose porous material, can the chemical bond said medicine, said medicine has suitable molecular structure in certain pH value and certain solution environmental in addition, can with soluble stanching gauze by electrostatic attraction and combination, so can realize the quantitative chemical combination.Reach excellent sterilization, sterilization, analgesic effect.
5. cationic surfactant such as benzene are pricked bromine ammonia antibacterial activity and all better than ever antibacterials of antimicrobial spectrum, are more suitable for being used for the prevention and the treatment of traumatic infection, can reduce the side effect of local analgesia agent simultaneously.Cationic surfactant such as benzene bundle bromine ammonia makes the product dissolving back of this claim be easier to antibacterials are separated from gauze under the attack of hydrone with the combination of gauze in addition, thereby can better bring into play antibacterial action.
6. added aminoacid is one of necessary aminoacid of human body, provides essential nutritional labeling for promoting tissue repair and wound healing.Therefore add this product behind the aminoacid and have the effect of significant promotion wound healing.
The specific embodiment
Enumerate embodiment below, the present invention is further specified, but the present invention is not only limited to these embodiment.
Embodiment 1
Configuration concentration is 85% alcoholic solution, the sodium hydrogen phosphate that adds 0.2kg, 1.5kg sodium alginate, the carbomer of 1kg, the benzalkonium bromide that adds 6kg then, elevated temperature to 45 ℃, stir, add soluble stanching gauze, stir or the condition of ultrasonic vibrations under carry out dynamic chemical and take out gauze after in conjunction with 8 hours, the continuous Polyethylene Glycol that adds 1.5kg in original liquid, the 3kg tween 80,0.5kg dimethicone, 0.5kg sodium carboxymethyl cellulose, the semi-finished product gauze is put into medicinal liquid, proceeded dynamic adsorption 2 hours under 45 ℃, and took out, the drying with steam oven dry gets product.
Embodiment 2-6
Prepare a kind of antiinflammatory, antibiotic analgesic soluble stanching gauze according to embodiment 1 described method, raw materials used and proportioning such as following table:
| Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | Embodiment 6 | |
| Sodium hydrogen phosphate | 0.1 | 0.15 | 0.3 | 0.25 | 0.2 |
| Sodium alginate | 1.5 | 1.2 | 1 | 1.8 | 1.6 |
| Carbomer | 1.3 | 0.5 | 2 | 1.5 | 1 |
| Benzalkonium bromide | 10 | 6 | |||
| Benzalkonium chloride | 5 | 8 | 1 | ||
| Polyethylene Glycol | 2 | 1.2 | 1.8 | 1.5 | 1 |
| Tween-80 | 2 | 1 | 4 | 3 | 2.5 |
| Dimethicone | 0.4 | 0.6 | 0.1 | 1 | 0.5 |
| Sodium carboxymethyl cellulose | 0.8 | 0.4 | 0.6 | 0.2- | 0.5 |
| Benzocaine | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Aminoacid | 0 | Tryptophan 0.01 | Methionine 0.02 | Threonine 0.05 | Leucine 0.01 |
| Alcoholic solution | Concentration 85% alcoholic solution 81.85 | Concentration 90% alcoholic solution 89.89 | Concentration 95% alcoholic solution 82.13 | Concentration 80% alcoholic solution 89.85 | Concentration 85% alcoholic solution 86.64 |
The product of the embodiment of the invention 1 is carried out the zoopery contrast with the product that obtains the processing method production of introducing among the Chinese patent ZL02135172.4 of domestic patent, 80 of choosing test rats, random packet, test group and matched group are 40 examples, skin to back 2*2cm after test group and the control rats unhairing carries out aseptic process, two groups of rats all alternately inoculate the positive bacteria in the same culture dish at random, test group is carried out antibacterial therapy with this patent product then, and matched group uses the product of the processing method production of introducing among the Chinese patent ZL02135172.4 of same area to treat.Test the healing state of observing wound surface after three days.To the evaluation of healing state, according to surgery evaluation methodology commonly used: it is good that first class healing, wound do not have red and swollen healing; The second class healing, wound circumference has redness or poroma, but does not have suppuration; The third class healing, wound is suppurative infection.Add up the case load of two treated animal first, second, the third three grades of healings respectively.Heal as the good evaluation criterion of Disinfection Effect with first class.Experimental result is as follows:
| Group | The first class healing | The second class healing | The third class healing |
| Test group | 40(100％) | 0 | 0 |
| Matched group | 30(75) | 0 | 0 |
Above-mentioned data are carried out statistical procedures with X 2 test.Compare P＜0.05 between group, this patent product is compared antibacterial effect with the matched group product the significance progress.
The product of the embodiment of the invention 1 is carried out the zoopery contrast with having obtained the product that the processing method introduced among the Chinese patent ZL02135172.4 of domestic patent produces, find that this product is in analgesia with prevent from all to compare according to set product aspect the tissue adhesion marked improvement (P＜0.05) is arranged.Experimental result is as follows:
| Group | Analgesic effect is good | Analgesic effect is poor |
| Test group | 40(100％) | 0 |
| Matched group | 0(100％) | 40 |
| Group | Tissue adhesion example number | No tissue adhesion example number |
| Test group | 0 | 39(97.5％) |
| Matched group | 15 | 25(62.5％) |
Claims (6)
1. an antiinflammatory, antibiotic analgesic soluble stanching gauze, constitute the sodium hydrogen phosphate of 0.1-0.3%, the sodium alginate of 1-1.8%, the carbomer of 0.5-2% by the material of following weight percentage ratio, the cationic surfactant of 1-10%, the Polyethylene Glycol of 1-2%, 1-4% tween 80,0.1-1% dimethicone, 0.2-0.8% sodium carboxymethyl cellulose, all the other are alcoholic solution more than 80% for concentration for 0.05% benzocaine.
2. antiinflammatory according to claim 1, antibiotic analgesic soluble stanching gauze is characterized in that described cationic surfactant is benzalkonium bromide or benzalkonium chloride.
3. antiinflammatory according to claim 1, antibiotic analgesic soluble stanching gauze, it is characterized in that, material by following weight percentage ratio constitutes: the carbomer of 0.2% sodium hydrogen phosphate, the sodium alginate of 1.2-1.6%, 1-1.5%, the cationic surfactant of 5-8%, the Polyethylene Glycol of 1.2-1.8%, 2-3% tween 80,0.4-0.6% dimethicone, 0.4-0.6% sodium carboxymethyl cellulose, 0.05% benzocaine, all the other are the alcoholic solution of 85-95% for concentration.
4. antiinflammatory according to claim 1, antibiotic analgesic soluble stanching gauze is characterized in that, also comprise the aminoacid of 0-0.05%.
5. the preparation method of antiinflammatory according to claim 1, antibiotic analgesic soluble stanching gauze:
Configuration concentration is the alcoholic solution more than 80%, add sodium hydrogen phosphate, sodium alginate, carbomer, add cationic surfactant then, elevated temperature is to 45-85 ℃, stir, add soluble stanching gauze, after dynamic chemical under the condition of stirring or ultrasonic vibrations was in conjunction with 0.5-60 hour, take out gauze, continuous Polyethylene Glycol, tween 80, dimethicone, the sodium carboxymethyl cellulose of adding in original liquid, the semi-finished product gauze is put into medicinal liquid, proceed dynamic chemical in conjunction with 1-30 hour under 45-85 ℃, take out, oven dry gets product.
6. antiinflammatory according to claim 4, the preparation method of antibiotic analgesic soluble stanching gauze: configuration concentration is the alcoholic solution of 85-99%, add aminoacid, elevated temperature is to 50-70 ℃, add glycerol, add cationic surfactant, the adjusting pH value is 8-12, boiling reflux 2-4 hour, add sodium hydrogen phosphate then, sodium alginate, carbomer, elevated temperature stirs to 50-70 ℃, add soluble stanching gauze, after dynamic chemical under the condition of stirring or ultrasonic vibrations was in conjunction with 4-15 hour, take out gauze, the continuous Polyethylene Glycol that adds in original liquid, tween 80, dimethicone, sodium carboxymethyl cellulose is put into medicinal liquid with the semi-finished product gauze, regulating the p H-number is 3-6.8, proceed dynamic chemical in conjunction with 4-15 hour under 50-70 ℃, take out, oven dry gets product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101353603A CN100379464C (en) | 2005-12-31 | 2005-12-31 | Soluble hemostatic gauze for diminishing inflammation, killing bacteria and calming pain, and its making method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101353603A CN100379464C (en) | 2005-12-31 | 2005-12-31 | Soluble hemostatic gauze for diminishing inflammation, killing bacteria and calming pain, and its making method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1803203A true CN1803203A (en) | 2006-07-19 |
| CN100379464C CN100379464C (en) | 2008-04-09 |
Family
ID=36865431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101353603A Active CN100379464C (en) | 2005-12-31 | 2005-12-31 | Soluble hemostatic gauze for diminishing inflammation, killing bacteria and calming pain, and its making method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100379464C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106835671A (en) * | 2016-12-22 | 2017-06-13 | 马鞍山市鑫程纳米新材料科技有限公司 | A kind of method for improving non-woven fabrics tensile strength |
| CN114432485A (en) * | 2022-02-15 | 2022-05-06 | 周建大 | pH-responsive quaternary ammonium salt antibacterial dressing and preparation method thereof |
| CN115957367A (en) * | 2022-12-02 | 2023-04-14 | 浙江兄弟控优生物科技有限公司 | High-biocompatibility coating liquid and hydrophobic antibacterial gauze dressing |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1045354A (en) * | 1989-03-10 | 1990-09-19 | 铁汉 | Non-adhesive gauze for reducing inflammation and accelerating recovery |
| CN1047976A (en) * | 1989-06-12 | 1990-12-26 | 湖南省衡阳卫生材料厂 | A kind of improvement of hemostatic gauze production method |
| US6809231B2 (en) * | 2001-11-21 | 2004-10-26 | The United States Of America As Represented By The Secretary Of Agriculture | Flexible and absorbent alginate wound dressing |
| CN1190196C (en) * | 2002-07-11 | 2005-02-23 | 张博 | Anti-inflammation antibiotic external used synthesized medicine, soluble hemostatic gauze and method for making the same |
-
2005
- 2005-12-31 CN CNB2005101353603A patent/CN100379464C/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106835671A (en) * | 2016-12-22 | 2017-06-13 | 马鞍山市鑫程纳米新材料科技有限公司 | A kind of method for improving non-woven fabrics tensile strength |
| CN114432485A (en) * | 2022-02-15 | 2022-05-06 | 周建大 | pH-responsive quaternary ammonium salt antibacterial dressing and preparation method thereof |
| CN115957367A (en) * | 2022-12-02 | 2023-04-14 | 浙江兄弟控优生物科技有限公司 | High-biocompatibility coating liquid and hydrophobic antibacterial gauze dressing |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100379464C (en) | 2008-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100471528C (en) | Liquid wound-dressing with functions of promoting heal of wound and bacterial-resisting | |
| KR102608156B1 (en) | Composition for treating wounds | |
| WO2019091150A1 (en) | Alginate wound repair dressing and preparation method thereof | |
| CN100379465C (en) | Inflammation-eliminating, pain-stopping, bacteria-resisting, pain-relieving soluble hemostatic gauze and its processing method | |
| CN103083712A (en) | Stem cells or other bioactive substances doped surgical dressing | |
| CN111068103A (en) | Long-acting antibacterial gel dressing for operation wound and preparation method thereof | |
| CN111150838A (en) | Collagen hydrogel for promoting wound healing and preparation method thereof | |
| CN110876814A (en) | Liquid band-aid rich in antibacterial peptide and preparation method thereof | |
| CN103495174B (en) | Be used for the treatment of Multi-effect external preparation of Dermal skin damage and uses thereof | |
| CN104784103B (en) | Based on oligomeric amino acid amphiphile, amphiphilic molecule injectable anti-bacterial hydrogel | |
| CN100379464C (en) | Soluble hemostatic gauze for diminishing inflammation, killing bacteria and calming pain, and its making method | |
| CN113018499A (en) | Preparation method of ozone oil-water gel composite application capable of sterilizing, resisting virus and absorbing moisture | |
| CN103316330B (en) | A kind of prescription of soft-tissue trauma nursing material and purposes | |
| Gupta et al. | Aloe vera loaded poly (vinyl alcohol)–poly (ethylene oxide)-carboxymethyl cellulose-polyester nonwoven membranes | |
| CN111632188A (en) | Seaweed polysaccharide composite biological matrix dressing and preparation method thereof | |
| CN111991417A (en) | Hypochlorous acid gel with physiological responsiveness and application thereof in skin wound surface | |
| CN117084970A (en) | Supermolecule hydrogel based on natural plant components, preparation and application thereof | |
| CN102526121B (en) | Wound repair composition and preparation method and application thereof | |
| CN109200326A (en) | Dressing and bandage for wound healing | |
| CN107595819A (en) | A kind of Nano diamond modified liquid adhesive bandage and preparation method thereof | |
| CN103721248A (en) | Chitosan oral mucosa ulcer patch | |
| CN107929725A (en) | A kind of environmentally friendly lysine polypeptide skin care thimerosal and its preparation process | |
| CN1190196C (en) | Anti-inflammation antibiotic external used synthesized medicine, soluble hemostatic gauze and method for making the same | |
| CN113967192A (en) | Pharmaceutical composition for accelerating wound healing, preparation method and application thereof | |
| CN107811958B (en) | Black tea fungus fermentation lubricating liquid and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Qingdao Etsong Bioengineering Co., Ltd. Assignor: Zhang Bo Contract fulfillment period: 2008.11.6 to 2025.12.30 Contract record no.: 2008370000212 Denomination of invention: Soluble hemostatic gauze for diminishing inflammation, killing bacteria and calming pain, and its making method Granted publication date: 20080409 License type: Exclusive license Record date: 20081222 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.11.6 TO 2025.12.30; CHANGE OF CONTRACT Name of requester: QINGDAO YIZHONG BIOLOGY ENGINEERING CO., LTD. Effective date: 20081222 |
|
| DD01 | Delivery of document by public notice |
Addressee: Zhang Bo Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Bo Document name: Notification of Termination of Patent Right |
|
| DD01 | Delivery of document by public notice | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210730 Address after: 266000 No. 592-16, jiushui East Road, Laoshan District, Qingdao City, Shandong Province Patentee after: Qingdao Zhonghui Shengxi Bioengineering Co.,Ltd. Address before: Donghai West Road 266071 Shandong city of Qingdao province No. 35 unit 13 C households Patentee before: Zhang Bo |
|
| TR01 | Transfer of patent right |